Fulgent Genetics (NASDAQ: FLGT)
Key Data Points
Fulgent Genetics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Fulgent Genetics Company Info
Fulgent Genetics is a technology company that provides comprehensive diagnostic genetic testing using its proprietary platform, which integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools, and integrated laboratory processes.
News & Analysis
Fulgent Genetics Revenue Tops Estimates
Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.
Fulgent Genetics: EPS Exceeds Forecast
The company is successfully pivoting away from COVID-19 services.
Fulgent Genetics Q2: Core Revenue Grows, but Profitability Is Still an Issue
The genetic testing company's core business is growing, but it's still generating red ink.
Got $2,500? This Dirt Cheap Growth Stock Could Be Worth Buying Hand Over Fist
Fulgent is moving past its pandemic-era business, and that's a good thing.
1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings
Strong core business growth was overshadowed in Q3 by an acquisition.
Why I Bought More of This Under-the-Radar Stock
This healthcare business has tailwinds behind it.
2 No-Brainer Stocks to Buy Right Now for Less than $55
These companies have low share prices and high potential.
This Stock Grew 135% Last Year and Is Down 50% From Its Highs
Is Fulgent an underrated stock or a value trap?
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.